These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 21394100

  • 21. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
    Luo Q, Pan W, Zhou S, Wang G, Yi H, Zhang L, Yan X, Yuan L, Liu Z, Wang J, Chen H, Qiu M, Yang D, Sun J.
    Oncol Res; 2020 Sep 01; 28(4):331-344. PubMed ID: 32093809
    [Abstract] [Full Text] [Related]

  • 22. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.
    Vaseva AV, Marchenko ND, Moll UM.
    Cell Cycle; 2009 Jun 01; 8(11):1711-9. PubMed ID: 19411846
    [Abstract] [Full Text] [Related]

  • 23. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, Liu L.
    J Cancer Res Clin Oncol; 2010 Oct 01; 136(10):1597-604. PubMed ID: 20174822
    [Abstract] [Full Text] [Related]

  • 24. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
    Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev LT, Myklebost O.
    BMC Cancer; 2011 May 30; 11():211:1-11. PubMed ID: 21624110
    [Abstract] [Full Text] [Related]

  • 25. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
    Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castaño E, Acebes JJ, Giménez-Bonafé P, Gil J, Tortosa A.
    PLoS One; 2011 Apr 05; 6(4):e18588. PubMed ID: 21483692
    [Abstract] [Full Text] [Related]

  • 26. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S.
    Leukemia; 2009 Nov 05; 23(11):2090-101. PubMed ID: 19710698
    [Abstract] [Full Text] [Related]

  • 27. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M.
    Blood; 2006 Aug 01; 108(3):993-1000. PubMed ID: 16543464
    [Abstract] [Full Text] [Related]

  • 28. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R, Gupta G, Manohar M, Debnath U, Popli P, Prabhakar YS, Konwar R, Kumar S, Kumar A, Dwivedi A.
    Int J Biochem Cell Biol; 2016 Jan 01; 70():105-17. PubMed ID: 26556313
    [Abstract] [Full Text] [Related]

  • 29. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
    Crane EK, Kwan SY, Izaguirre DI, Tsang YT, Mullany LK, Zu Z, Richards JS, Gershenson DM, Wong KK.
    PLoS One; 2015 Jan 01; 10(8):e0135101. PubMed ID: 26248031
    [Abstract] [Full Text] [Related]

  • 30. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.
    Duan L, Perez RE, Chen L, Blatter LA, Maki CG.
    J Mol Cell Biol; 2018 Aug 01; 10(4):331-340. PubMed ID: 29190376
    [Abstract] [Full Text] [Related]

  • 31. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.
    Trino S, Iacobucci I, Erriquez D, Laurenzana I, De Luca L, Ferrari A, Ghelli Luserna Di Rorà A, Papayannidis C, Derenzini E, Simonetti G, Lonetti A, Venturi C, Cattina F, Ottaviani E, Abbenante MC, Russo D, Perini G, Musto P, Martinelli G.
    Oncotarget; 2016 Mar 15; 7(11):12951-61. PubMed ID: 26887044
    [Abstract] [Full Text] [Related]

  • 32. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, Suzuki H, Abei M, Nakagawa I, Hyodo I.
    Cancer Sci; 2011 Mar 15; 102(3):605-13. PubMed ID: 21205074
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis.
    Bhattacharya S, Ray RM, Chaum E, Johnson DA, Johnson LR.
    Invest Ophthalmol Vis Sci; 2011 May 01; 52(6):3368-80. PubMed ID: 21345989
    [Abstract] [Full Text] [Related]

  • 34. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F.
    Oncogene; 2008 Sep 11; 27(40):5303-14. PubMed ID: 18521084
    [Abstract] [Full Text] [Related]

  • 35. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
    Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Bueno-Silva B, de Alencar SM, Lombardi P, Mao W, Montalto G, Cervello M, Rakus D, Gizak A, Lin HL, Libra M, Akula SM, McCubrey JA.
    Adv Biol Regul; 2019 May 11; 72():22-40. PubMed ID: 30898612
    [Abstract] [Full Text] [Related]

  • 36. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
    Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S.
    Cell Death Dis; 2011 Apr 21; 2(4):e148. PubMed ID: 21509038
    [Abstract] [Full Text] [Related]

  • 37. MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition.
    Schneider LS, Ulrich M, Lehr T, Menche D, Müller R, von Schwarzenberg K.
    Mol Oncol; 2016 Aug 21; 10(7):1054-62. PubMed ID: 27157929
    [Abstract] [Full Text] [Related]

  • 38. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
    Zhang L, Zhang J, Hu C, Cao J, Zhou X, Hu Y, He Q, Yang B.
    Anticancer Drugs; 2009 Jul 21; 20(6):416-24. PubMed ID: 19579266
    [Abstract] [Full Text] [Related]

  • 39. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
    He T, Guo J, Song H, Zhu H, Di X, Min H, Wang Y, Chen G, Dai W, Ma J, Sun X, Ma J.
    Pathol Oncol Res; 2018 Jan 21; 24(1):75-81. PubMed ID: 28341911
    [Abstract] [Full Text] [Related]

  • 40. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet JM, Kim ES.
    Angiogenesis; 2011 Sep 21; 14(3):255-66. PubMed ID: 21484514
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.